Literature DB >> 16695556

THE RELATION OF ALBUMIN TO PRECIPITABLE IODINE OF SERUM.

J P Peters1, E B Man.   

Abstract

Entities:  

Keywords:  ALBUMIN/pharmacology; IODINE AND COMPOUNDS/serum

Mesh:

Substances:

Year:  1948        PMID: 16695556      PMCID: PMC439506          DOI: 10.1172/JCI101982

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  9 in total

1.  SERUM LIPOIDS IN MALNUTRITION.

Authors:  E B Man; E F Gildea
Journal:  J Clin Invest       Date:  1936-03       Impact factor: 14.808

2.  SERUM IODINE FRACTIONS IN HYPERTHYROIDISM.

Authors:  E B Man; A E Smirnow; E F Gildea; J P Peters
Journal:  J Clin Invest       Date:  1942-11       Impact factor: 14.808

3.  SERUM IODINE OF EUTHYROID SUBJECTS TREATED WITH DESICCATED THYROID.

Authors:  D S Riggs; E B Man; A W Winkler
Journal:  J Clin Invest       Date:  1945-09       Impact factor: 14.808

4.  SERUM IODINE IN HYPOTHYROIDISM BEFORE AND DURING THYROID THERAPY.

Authors:  A W Winkler; D S Riggs; E B Man
Journal:  J Clin Invest       Date:  1945-09       Impact factor: 14.808

5.  THE LIPIDS OF SERUM AND LIVER IN PATIENTS WITH HEPATIC DISEASES.

Authors:  E B Man; B L Kartin; S H Durlacher; J P Peters
Journal:  J Clin Invest       Date:  1945-09       Impact factor: 14.808

6.  SERUM IODINE IN HYPERTHYROIDISM, WITH PARTICULAR REFERENCE TO THE EFFECTS OF SUBTOTAL THYROIDECTOMY.

Authors:  A W Winkler; D S Riggs; K W Thompson; E B Man
Journal:  J Clin Invest       Date:  1946-05       Impact factor: 14.808

7.  THE INTERRELATIONS OF SERUM LIPIDS IN PATIENTS WITH DISEASES OF THE KIDNEYS.

Authors:  J P Peters; E B Man
Journal:  J Clin Invest       Date:  1943-09       Impact factor: 14.808

8.  TOLERANCE TO ORAL THYROID AND REACTION TO INTRAVENOUS THYROXINE IN SUBJECTS WITHOUT MYXEDEMA.

Authors:  A W Winkler; P H Lavietes; C L Robbins; E B Man
Journal:  J Clin Invest       Date:  1943-07       Impact factor: 14.808

9.  ELECTROPHORETIC ANALYSIS OF PLASMA AND URINARY PROTEINS.

Authors:  J A Luetscher
Journal:  J Clin Invest       Date:  1940-03       Impact factor: 14.808

  9 in total
  15 in total

1.  Increased levothyroxine requirements presenting as "inappropriate" TSH secretion syndrome in a patient with nephrotic syndrome.

Authors:  M T Collins; A T Remaley; G Csako; F Pucino; M C Skarulis; J E Balow; N J Sarlis
Journal:  J Endocrinol Invest       Date:  2000-06       Impact factor: 4.256

2.  Effects of infusions of serum albumin on serum lipids and lipoproteins in nephrosis.

Authors:  J H BAXTER; H C GOODMAN; J C ALLEN
Journal:  J Clin Invest       Date:  1961-03       Impact factor: 14.808

3.  TERMINAL HYPERKALEMIA.

Authors:  R K CHANDRA
Journal:  Indian J Pediatr       Date:  1963-09       Impact factor: 1.967

4.  Thyroxine-binding by serum and urine proteins in nephrosis; qualitative aspects.

Authors:  J ROBBINS; J E RALL; M L PETERMANN
Journal:  J Clin Invest       Date:  1957-09       Impact factor: 14.808

5.  Thyroxine metabolism in the nephrotic syndrome.

Authors:  H RASMUSSEN
Journal:  J Clin Invest       Date:  1956-07       Impact factor: 14.808

6.  The interpretation of the serum protein-bound iodine: A review.

Authors:  J D Acland
Journal:  J Clin Pathol       Date:  1971-04       Impact factor: 3.411

7.  Protein-bound plasma iodine as an aid in the diagnosis of thyroid disease.

Authors:  W F PERRY; J B R COSGROVE
Journal:  Can Med Assoc J       Date:  1949-06       Impact factor: 8.262

8.  Studies of serum creatine tolerance. I. Findings in normal males and in hyperthyroidism.

Authors:  J H PETERS; R SCHWARTZ; H MERMELSTEIN; M N NEFORES; M M MANSUY
Journal:  J Clin Invest       Date:  1951-08       Impact factor: 14.808

9.  Precipitable iodine of serum (SPI) in disorders of the liver.

Authors:  D M KYDD; E B MAN
Journal:  J Clin Invest       Date:  1951-08       Impact factor: 14.808

10.  Thyroid function in nephrosis.

Authors:  L RECANT; D S RIGGS
Journal:  J Clin Invest       Date:  1952-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.